medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2004, Number 1

<< Back Next >>

Rev Mex Oftalmol 2004; 78 (1)

Tratamiento médico de la vitreorretinopatía proliferativa con colchicina oral

González KRN, Graue WFA

Language: Spanish
References: 11
Page: 13-16
PDF size: 197.08 Kb.


ABSTRACT

Purpose: To determine if oral therapeutic – dose colchicine have an inhibitory effect on proliferative vitreoretinopathy.
Material and method: We studied 80 patients who underwent vitrectomy with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. 40 consecutive patients were assigned to a control group and the other 40 received oral colchicine (1.5 mg/day). Medication started the first day after surgery and continued for four weeks. The follow-up period was three months. Data obtained in both groups were compared.
Results: 23 of 40 (57.5%) patients in the control group and 26 of 40 (65%) patients in the colchicine group had flat retinas during the follow up period. There was retinal redetachment in 15 of 40 (37.5%) patients in the control group and in 13 of 40 (32.5%) patients in the colchicines group.
Conclusion: Therapeutic–safe dosages of colchicine do not significantly inhibit proliferative vitreoretinopathy.


REFERENCES

  1. Raymond M, Thompson J. RPE-mediated collagen gel contraction. Inhibition by colchicine and stimulation by TGFbeta. Investigative Ophthalmology Visual Science, 1990; 31(6).

  2. Faude F, Heimann K, Wiedemann P. A survey of clinically used drugs in PVR: a review. Klin Monatsbl Augenheilkd, 1999; 214(6):362-366.

  3. Wiedemann P. Drug treatment of proliferative vitreoretino-pathy. Fortschr Ophthalmol, 1989; 86(2):115-120.

  4. Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina, 1983; 3(4):269-272.

  5. McDonnell PJ, Krause W, Glaser BM. In vitro inhibition of lens epithelial cell proliferation and migration. Ophtalmic Surg, 1988; 19(1):25-30.

  6. Lemor M, Yeo J, Glaser B. Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol, 1986; 104(8):1226-1229.

  7. Verdoorn C, Renardel de Lavalette VW, Dalma-Weizhausz J, Orr GM, Sorgente N, Ryan SJ. Cellular migration, proliferation and contraction. An in vitro approach to a clinical problem—proliferative vitreoretinopathy. Arch Ophthalmol, 1986;104(8):1216-1219.

  8. Quiroz H, Cárdenas F, Arellanes L, Aguirre R, Gomez A. Inhibición de proliferaciones intraoculares con colchicina intravítrea. Arch APEC, 1984; 3(1): 5-8.

  9. Machemer R, Aaberg T, Freeman M, Irvine A, Lean J, Michels R. An Update Classification of Retinal Detachment with Proliferative Vitreoretinopathy. Am J Ophtalmol, 1991; 112:159-165.

  10. Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surg, 1989; 20(4):268-272.

  11. Huna R, Moisseiev J, Dany S, Ezra D. Intraocular penetration of colchicine after oral administration. Invest Ophthal Vis Sci, 1994; 35(4).




2020     |     www.medigraphic.com